Moreover, GRHL3 expression in a subset of head and neck cancer patients induces tumour differentiation through induction of its tumour-specific target gene FLG and this differentiation potentially influences anti-cancer therapy responses and patient prognosis [137]. This evidence concerns the gene GRHL3 and neoplasm.